SK125999A3 - Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors - Google Patents

Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors Download PDF

Info

Publication number
SK125999A3
SK125999A3 SK1259-99A SK125999A SK125999A3 SK 125999 A3 SK125999 A3 SK 125999A3 SK 125999 A SK125999 A SK 125999A SK 125999 A3 SK125999 A3 SK 125999A3
Authority
SK
Slovakia
Prior art keywords
alloy
phenyl
chromium
pyrrolo
pyrimidin
Prior art date
Application number
SK1259-99A
Other languages
English (en)
Slovak (sk)
Inventor
David John Calderwood
David Norman Johnston
Paul Rafferty
Helen Louise Twigger
Rainer Munschauer
Lee Arnold
Original Assignee
Knoll Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Ag filed Critical Knoll Ag
Publication of SK125999A3 publication Critical patent/SK125999A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1259-99A 1997-03-19 1998-03-09 Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors SK125999A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4083697P 1997-03-19 1997-03-19
PCT/EP1998/001357 WO1998041525A1 (en) 1997-03-19 1998-03-09 Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
SK125999A3 true SK125999A3 (en) 2000-05-16

Family

ID=21913242

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1259-99A SK125999A3 (en) 1997-03-19 1998-03-09 Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors

Country Status (23)

Country Link
US (1) US6001839A (xx)
EP (1) EP0970084B1 (xx)
JP (1) JP2001516353A (xx)
KR (1) KR20000076426A (xx)
CN (1) CN1134439C (xx)
AT (1) ATE242245T1 (xx)
AU (1) AU748884B2 (xx)
BG (1) BG64282B1 (xx)
BR (1) BR9808281A (xx)
CA (1) CA2283961A1 (xx)
DE (1) DE69815317T2 (xx)
DK (1) DK0970084T3 (xx)
ES (1) ES2202827T3 (xx)
HU (1) HUP0001507A3 (xx)
ID (1) ID24653A (xx)
IL (1) IL131582A0 (xx)
NO (1) NO313962B1 (xx)
NZ (1) NZ337529A (xx)
PL (1) PL335685A1 (xx)
PT (1) PT970084E (xx)
SK (1) SK125999A3 (xx)
TR (1) TR199902301T2 (xx)
WO (1) WO1998041525A1 (xx)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
CA2341409A1 (en) * 1998-08-31 2000-03-09 Merck And Co., Inc. Novel angiogenesis inhibitors
JP2002526500A (ja) * 1998-09-18 2002-08-20 ビーエーエスエフ アクチェンゲゼルシャフト プロテインキナーゼ阻害剤としてのピロロピリミジン
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
EP1212327B8 (en) 1999-09-17 2004-02-25 Abbott GmbH & Co. KG Pyrazolopyrimidines as therapeutic agents
CA2385769A1 (en) * 1999-09-17 2001-03-22 Gavin C. Hirst Kinase inhibitors as therapeutic agents
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
US7369946B2 (en) 2000-03-29 2008-05-06 Abbott Gmbh & Co. Kg Method of identifying inhibitors of Tie-2
MXPA02009543A (es) * 2000-03-29 2005-08-26 Abbott Gmbh & Co Kg Metodo para identificar inhibidores de tie-2.
KR100403860B1 (ko) * 2000-12-27 2003-11-01 엘지전자 주식회사 차세대 이동통신 시스템의 접속시도시의 충돌감소를 위한알에이씨에이치 선택방법
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
TWI238824B (en) * 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
AP2003002929A0 (en) * 2001-06-23 2003-12-31 Aventis Pharma Inc Pyrrolopyrimidines as protein kinase inhibitors
PT1401415E (pt) 2001-06-29 2006-09-29 Ab Science Utilizacao de derivados de n-fenil-2-pirimidino-amina para o tratamento de doencas inflamatorias
US20040266771A1 (en) * 2001-06-29 2004-12-30 Alain Moussy Use of tyrosine kinase inhibitors for treating bone loss
DE60227709D1 (de) * 2001-06-29 2008-08-28 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
EP1434991B1 (en) 2001-06-29 2007-10-17 AB Science New potent, selective and non toxic c-kit inhibitors
CA2452167A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
ATE343415T1 (de) * 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
EP1425284A2 (en) * 2001-09-11 2004-06-09 Smithkline Beecham Corporation Furo- and thienopyrimidine derivatives as angiogenesis inhibitors
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
AU2003246972A1 (en) 2002-08-06 2004-02-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US20050008640A1 (en) * 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
WO2004100947A2 (en) * 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
BRPI0416656A (pt) * 2003-11-17 2007-01-16 Pfizer Prod Inc compostos de pirrolopirimidina úteis no tratamento do cáncer
CA2553724A1 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
GB0403606D0 (en) * 2004-02-18 2004-03-24 Novartis Ag Organic compounds
JP4842929B2 (ja) * 2004-05-27 2011-12-21 ファイザー・プロダクツ・インク 癌治療に有用なピロロピリミジン誘導体
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
CA2601766A1 (en) * 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
RU2008117151A (ru) * 2005-09-30 2009-11-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Деазапурины, пригодные в качестве ингибиторов янус-киназ
RS51843B (en) * 2005-11-17 2012-02-29 Osi Pharmaceuticals Llc. CONDENSED BICYCLIC m TOR INHIBITORS
CN101336244B (zh) * 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
WO2007087395A2 (en) * 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
EP1983971A4 (en) * 2006-01-25 2010-11-24 Synta Pharmaceuticals Corp SUBSTITUTED AROMATIC COMPOUNDS FOR USE AGAINST INFLAMMATION AND IMMUNE DISORDERS
MX2008012928A (es) 2006-04-04 2009-03-06 Univ California Antagonistas de pi3-cinasa.
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
EP2201840B1 (en) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
EP1969934A1 (de) * 2007-03-12 2008-09-17 Bayer CropScience AG 4-Cycloalkyl-oder 4-arylsubstituierte Phenoxyphenylamidine und deren Verwendung als Fungizide
EP2548558A1 (en) * 2007-03-28 2013-01-23 Pharmacyclics, Inc. Nitrogen-containing condensed heterocyclic as inhibitors of bruton's tyrosine kinase
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN104926815B (zh) 2008-01-04 2017-11-03 英特利凯恩有限责任公司 某些化学实体、组合物和方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン, エルエルシー キナーゼ阻害剤および使用方法
US8557814B2 (en) * 2008-03-19 2013-10-15 OSI Pharmaceuticals, LLC mTOR inhibitor salt forms
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US8697709B2 (en) * 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
CN103002738A (zh) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 用于激酶调节的化学化合物、组合物和方法
MY191929A (en) 2010-06-03 2022-07-18 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
BR112013017670B1 (pt) 2011-01-10 2022-07-19 Infinity Pharmaceuticals, Inc Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
FR2970967B1 (fr) 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
WO2012148540A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kanase inhibitors and uses threof
CN103534257A (zh) * 2011-04-05 2014-01-22 辉瑞有限公司 作为原肌球蛋白相关激酶抑制剂的吡咯并[2,3-d]嘧啶衍生物
WO2013010136A2 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104470515B (zh) 2012-05-03 2016-12-07 圣路易斯药学院 用于增加神经营养肽的组合物和方法
TWI662964B (zh) 2012-06-04 2019-06-21 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
RU2015115631A (ru) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
SG11201503842PA (en) 2012-11-15 2015-06-29 Pharmacyclics Inc Pyrrolopyrimidine compounds as kinase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN103333096A (zh) * 2013-06-25 2013-10-02 苏州大学 一种化学选择性制备多功能吡咯衍生物的新方法
MA38961A1 (fr) 2013-09-30 2018-05-31 Pharmacyclics Llc Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
MX2017001671A (es) 2014-08-07 2017-07-04 Pharmacyclics Llc Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TWI810588B (zh) 2015-03-03 2023-08-01 美商製藥公司 布魯東氏(bruton’s)酪胺酸激酶抑制劑之醫藥調配物
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3472165B1 (en) 2016-06-21 2023-09-06 Nerviano Medical Sciences S.r.l. N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
DK3612519T3 (da) 2017-04-18 2022-03-07 Lilly Co Eli Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
EP3810574A1 (en) 2018-06-21 2021-04-28 Cellestia Biotech AG Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts
AU2019323444A1 (en) * 2018-08-22 2021-04-15 Jiangsu Hengrui Medicine Co., Ltd. Preparation method of pyrrolo-amino-pyridazinone compound and intermediate thereof
MX2021012359A (es) * 2019-04-10 2022-01-19 Cellestia Biotech Ag Inhibidores de la vía de señalización de notch y su uso en el tratamiento de cánceres.
EP4306529A3 (en) * 2019-05-13 2024-04-10 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
CN110483523B (zh) * 2019-08-27 2022-11-22 药雅科技(上海)有限公司 一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
EP4021908A1 (en) * 2019-08-29 2022-07-06 Hibercell, Inc. Perk inhibiting pyrrolopyrimidine compounds
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
WO2021184154A1 (en) 2020-03-16 2021-09-23 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
CA3198943A1 (en) 2020-11-18 2022-05-27 Daniel L. Flynn Gcn2 and perk kinase inhibitors and methods of use thereof
TW202233625A (zh) * 2020-11-18 2022-09-01 美商傳達治療有限公司 Fgfr抑制劑及其製造及使用方法
CA3231948A1 (en) * 2021-09-23 2023-03-30 Jingyu Hu Fgfr inhibitors and methods of use thereof
CN118369322A (zh) * 2021-12-06 2024-07-19 英矽智能科技(上海)有限公司 取代的单环或双环杂环化合物,其制法与医药上的用途
CN116903628A (zh) * 2022-04-20 2023-10-20 深圳福沃药业有限公司 Fgfr2抑制剂及使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033752A1 (en) * 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
PT783505E (pt) * 1994-09-29 2001-08-30 Novartis Ag Pirrolo¬2,3-d|pirimidinas e sua utilizacao
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US5665721A (en) * 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
CH690773A5 (de) * 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU1794697A (en) * 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
US6051577A (en) * 1996-03-15 2000-04-18 Novartis Ag N-7-heterocyclyl pyrrolo[2,3-D]pyrimidines and the use thereof

Also Published As

Publication number Publication date
DE69815317D1 (de) 2003-07-10
IL131582A0 (en) 2001-01-28
CA2283961A1 (en) 1998-09-24
EP0970084B1 (en) 2003-06-04
ATE242245T1 (de) 2003-06-15
PT970084E (pt) 2003-10-31
PL335685A1 (en) 2000-05-08
BR9808281A (pt) 2000-05-16
CN1134439C (zh) 2004-01-14
HUP0001507A2 (hu) 2000-10-28
JP2001516353A (ja) 2001-09-25
BG103785A (en) 2000-06-30
NO994509L (no) 1999-09-17
NZ337529A (en) 2000-10-27
NO313962B1 (no) 2003-01-06
DK0970084T3 (da) 2003-09-29
ES2202827T3 (es) 2004-04-01
DE69815317T2 (de) 2005-04-07
BG64282B1 (bg) 2004-08-31
TR199902301T2 (xx) 1999-12-21
ID24653A (id) 2000-07-27
KR20000076426A (ko) 2000-12-26
AU748884B2 (en) 2002-06-13
CN1259950A (zh) 2000-07-12
NO994509D0 (no) 1999-09-17
US6001839A (en) 1999-12-14
HUP0001507A3 (en) 2002-01-28
AU6829398A (en) 1998-10-12
WO1998041525A1 (en) 1998-09-24
EP0970084A1 (en) 2000-01-12

Similar Documents

Publication Publication Date Title
SK125999A3 (en) Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
US8329716B2 (en) Hetaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors
CA2692859C (en) Imidazo-, pyrazolopyrazines and imidazotriazines and their use
JP5400626B2 (ja) 置換イミダゾおよびトリアゾロピリミジン類
JP5507546B2 (ja) 置換イミダゾ−およびトリアゾロピリミジン類、イミダゾ−およびピラゾロピラジン類およびイミダゾトリアジン類
US20080287468A1 (en) Purine and imidazopyridine derivatives for immunosuppression
US20010025043A1 (en) New pharmaceutical active compounds
US20030191307A1 (en) 2,4-Diaminopyrimidine compounds useful as immunosuppressants
CA2669686A1 (en) 7-substituted purine derivatives for immunosuppression
NZ505079A (en) Pyrazolotriazines and pyrazolopyrimidines useful as corticotropin releasing factor antagonists
TW200831104A (en) 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
TW200304818A (en) Kinase inhibitors
TW200837064A (en) 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
KR20080081177A (ko) 야누스 키나아제 억제제인 술폰아미도아닐린 유도체
KR20190002468A (ko) N-[2-(3-히드록시-3-메틸부틸)-6-(2-히드록시프로판-2-일)-2h-인다졸-5-일]-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 결정질 형태
EP2521726B1 (fr) Dérivés de 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine comme inhibiteurs de kinases camkii pour le traitement de maladies cardiovasculaires
JP2011506364A (ja) トリアゾロトリアジンおよびトリアゾロピラジンおよびそれらの使用
SK286461B6 (sk) [1,5-a]-Pyrazolo-1,3,5-triazíny, ich použitie a farmaceutické kompozície na ich báze
MXPA99008171A (es) Agentes terapeuticos
CZ328399A3 (cs) Derivát pyrrolo[2,3d]pyrimidinu, způsob jeho přípravy a jeho použití
TW201004620A (en) Heterocyclic compound and use thereof